Cotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
37 Amino Acids · MW: ~4,700 Da
Amino Acids
37
Molecular Weight
~4,700 Da
Half-life
Approximately 24 hours
Research Score
4.2
Studies
18
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Cotadutide?
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Key Benefits & Mechanisms
body-weight reduction
improved insulin sensitivity
reduced hepatic fat
appetite suppression
Research Summary
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Related Peptides
Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Weight ManagementMazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight ManagementLixisenatide
Exendin-4-derived GLP-1 receptor agonist
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4. It is best known for postprandial glucose control, with modest secondary weight loss in clinical use.
Weight Management